Flu mortality formula is potentially misleading, say scientists

Calculating the case fatality ratio is tricky, according to new research - News Release

Imperial College London News Release

Under strict embargo for
00.01 British Summer Time
Wednesday 15 July 2009

A standard calculation used in forecasting potential numbers of deaths during the swine flu pandemic risks misleading healthcare planners by being open to both over- and under-estimation of the true figures, say the authors of new research published today in the British Medical Journal.

The proportion of people who die due to infection during an influenza outbreak - known as the case fatality ratio - is calculated by dividing the number of deaths by the total number of cases in the same time period. Early data from the current swine flu pandemic suggested that the new influenza A (H1N1) virus causes mild disease, with case fatality ratios of around 0.5%, or 5 deaths per 1000 people infected.

However, the researchers from the MRC Centre for Outbreak Analysis & Modelling at Imperial College London, say this ratio may not be accurate.

They highlight three reasons for the inaccuracy. Firstly, that the total number of deaths during this pandemic is being underestimated because the cause of death is not correctly attributed to swine flu (e.g. influenza can temporarily increase the risk of vascular events, such as heart attacks).

Secondly that as the pandemic progresses, the total number of cases tends towards underestimation, as people presenting with milder symptoms may not be tested or visit a doctor at all, leaving only the most severe to be reported.

Thirdly, that the 'snapshot' calculation does not take account of the time delay between infection and death, thus leading to the false impression that the infection is actually becoming more severe as the pandemic progresses.

Dr Tini Garske, lead author of the study from the MRC Centre for Outbreak Analysis & Modelling at Imperial College London, said:

"Accurately predicting the severity of this swine flu pandemic is a very tricky business, and our research shows that this can only be achieved if data is collected according to well designed study protocols and analysed in a more sophisticated way than is frequently being performed at present.

"If we fail to get an accurate prediction of severity, we will not be providing healthcare planners, doctors and nurses, with the information that they need to ensure they are best prepared to fight the pandemic as we head into the flu season this autumn.

Many mild cases may go unconfirmed, suggest researchers

The research was funded by a Medical Research Council UK Centre grant.

-Ends-

For further information please contact:

Lucy Goodchild
Press Officer
Imperial College London
e-mail: lucy.goodchild@imperial.ac.uk
Telephone: +44 (0)20 7594 6702 or ext. 46702
Out of hours Duty Press Officer: +44 (0)7803 886 248

Notes to editors:

1."Assessing the severity of the novel influenza A(H1N1) pandemic" British Medical Journal, 15 July 2009.
Lead author: Dr Tini Garske, Imperial College London
(For a full list of authors, please see paper)

2. The Medical Research Council is dedicated to improving human health through excellent science. It invests on behalf of the UK taxpayer. The results have led to some of the most significant discoveries in medical science and benefited the health and wealth of millions of people in the UK and around the world. Research ranges from molecular level science to public health research, carried out in universities, hospitals and a network of MRC units and institutes. The MRC liaises with the Health Departments, the National Health Service and industry to take account of the public's needs. www.mrc.ac.uk

3. About Imperial College London

Consistently rated amongst the world's best universities, Imperial College London is a science-based institution with a reputation for excellence in teaching and research that attracts 13,000 students and 6,000 staff of the highest international quality.

Innovative research at the College explores the interface between science, medicine, engineering and business, delivering practical solutions that improve quality of life and the environment - underpinned by a dynamic enterprise culture.

Since its foundation in 1907, Imperial's contributions to society have included the discovery of penicillin, the development of holography and the foundations of fibre optics. This commitment to the application of research for the benefit of all continues today, with current focuses including interdisciplinary collaborations to improve health in the UK and globally, tackle climate change and develop clean and sustainable sources of energy.

Website: www.imperial.ac.uk